Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.98-13.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GALT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GALT — earnings miss
Dated 2026-08-14
Results of Operations and Financial Condition. On August 14, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…
Why it matters: The FDA and Galectin aligned on the main trial parts, including the liver outcome and one dose. Changes could add time or cost.
Worry ifThe filed protocol keeps the composite liver outcome and blinded central endoscopy review. It also keeps one 2 mg/kg LBM dose.
Less concerning ifThe filed protocol changes any of the three agreed trial elements. Or, the company reports that the FDA wants more trial-design changes.
Why it matters: Galectin reported $13.2 million in cash and said funds covered planned work through June 2027. A delay or higher study costs could shorten that runway.
Worry ifThe November 13 results keep the stated cash runway through June 2027 and report no new funding need for planned work.
Less concerning ifThe November 13 results show the stated runway ends before June 2027. Or, they disclose new funding needs or trial delays due to cash limits.
Why it matters: Galectin says work on its cancer programs depends largely on finding a partner. A deal would show those programs can advance beyond the lead liver drug.
Supportive ifGalectin names a partner in a public filing or release. It says the partner will fund or run work on a cancer program.
Worry ifA company update says it has no partner and has paused or ended work on a cancer program.
Why it matters: The FDA agreed on key trial details. A filed protocol would mark progress toward testing belapectin in a larger trial.
Supportive ifA company filing or update confirms it sent the Phase 3 protocol to the FDA with the agreed trial design.
Worry ifThe company reports no submission by November 13, 2026. Or, it says the FDA asked for changes that delay the filing.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$291 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $918 loss on $10,000 · 9.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,805 loss on $10,000 · 68.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.